Posts by Raymond J. March
Raymond J. March is a Research Fellow and Director of FDAReview.org with the Independent Institute. He is also an Assistant Professor of Economics at Angelo State University where he is the Assistant Director of the Free Market Institute, Assistant Research Professor at Texas Tech University, Public Choice and Public Policy fellow with the American Institute for Economic Research, and an affiliated scholar with the Challey Institute for Global Innovation and Growth. His research has appeared in Health Economics, Southern Economic Journal, Public Choice, Research Policy, Food Policy, Journal of Institutional Economics, The Independent Review and other academic outlets. His popular articles have appeared in Fortune, Washington Examiner, National Interest, Washington Times, Sun Sentinel, The Hill, Real Clear Health, Medical News Daily. He earned his Ph.D. from Texas Tech University.
Politicians Still Misunderstand High Insulin Prices
Are More Vaping Bans Coming Soon? Let’s Hope Not!
Will FDA Approve Biogen’s Promising New Treatment for Alzheimer’s?
Only Markets Can Alleviate Drug Shortages
New FDA Commissioner, Same FDA Problem
Telemedicine Continues to Reach New Heights
Breakthrough Alzheimer’s Drug Puts FDA’s Drug-Approval Process into Question
Is Right-to-Try Legislation a Bust? Time for a Second Opinion.
Trust Walmart’s Insulin to Save Lives
FDA Investigates Supposed Link Between Vaping and Seizures
How Government Prolonged the Lobotomy
New Study Finds FDA in Contempt of the U.S. Constitution
Worried About Big Pharma? Then Reduce the FDA’s Regulatory Power.
As Insulin Prices Rise, Diabetics Turn to Black Markets
San Francisco’s Vaping Ban Is Doomed To Go Up in Smoke
Trump’s Executive Orders Won’t Lower Healthcare Prices, but Deregulation Will
Right-to-Try Legislation Helps Patient Battling Bone Cancer
FDA Approves $2 Million Drug. Blame the Price on Excessive Regulation.
FDA To Stop Regulating the Amount of Cherries in Frozen Cherry Pie
Political Rhetoric Against Right-to-Try Laws Continues, Undermining Support for Medical Treatments of Last Resort
FDA Approves Ketamine-Based Drug to Treat Difficult Cases of Depression
Generic Insulin Now Available After Nearly One Hundred Years of Regulatory Protection From Competition
FDA Wants More Sunscreen Regulations, but Would Consumers Get Burned?
FDA Panel Backs Ketamine-Based Treatment for Depression
Let Competition, Not Politicians, Bring Insulin Prices Down

  • Catalyst
  • Beyond Homeless
  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org